Literature DB >> 28064217

Clinical Factors Asssociated with Treatment Outcomes following Whole-brain Irradiation in Patients with Prostate Cancer.

Liesa Dziggel1, Steven E Schild2, Theo Veninga3, Amira Bajrovic4, Dirk Rades5.   

Abstract

BACKGROUND/AIM: Patients with prostate cancer represent a small minority of cancer patients presenting with metastases to the brain. This study investigated the role of whole-brain irradiation (WBI) in this rare group. PATIENTS AND METHODS: Eighteen such patients were included. Clinical factors including fractionation program of WBI, age at WBI, Karnofsky performance score (KPS), number of metastases to the brain, involvement of extracerebral metastatic sites, time from prostate cancer diagnosis to WBI and recursive-partitioning-analysis (RPA) class were investigated regarding local (intracerebral) control and survival.
RESULTS: On multivariate evaluation, longer time from prostate cancer diagnosis to WBI showed a trend towards improved local control (hazard ratio 2.77, p=0.098). Better KPS (hazard ratio 5.64, p=0.021) and longer time from prostate cancer diagnosis to WBI (hazard ratio 5.64, p=0.013) were significantly associated with better survival.
CONCLUSION: Two independent predictors of survival were identified and should be considered when designing for personalized treatment regimens and clinical trials. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Prostate cancer; WBI; local control; metastases to the brain; survival

Mesh:

Year:  2017        PMID: 28064217      PMCID: PMC5354144          DOI: 10.21873/invivo.11021

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  15 in total

1.  A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database.

Authors:  Paul W Sperduto; Brian Berkey; Laurie E Gaspar; Minesh Mehta; Walter Curran
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-10-10       Impact factor: 7.038

2.  Prophylactic Robotic-assisted Laparoscopic Radical Prostatectomy for Preoperative Suspicion of Prostate Cancer: Experience with 55 Cases.

Authors:  Yen-Chuan Ou; Wei-Chun Weng; Kuangh-Si Chang; Cheng-En Mei; Chun Kuang Yang; Siu-Wan Hung; John Wang; Min-Che Tung
Journal:  Anticancer Res       Date:  2016-09       Impact factor: 2.480

Review 3.  Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer.

Authors:  Federica Eleonora Buroni; Marco Giovanni Persico; Francesca Pasi; Lorenzo Lodola; Rosanna Nano; Carlo Aprile
Journal:  Anticancer Res       Date:  2016-11       Impact factor: 2.480

4.  Secreted Phosphoprotein 24 kD Inhibits Growth of Human Prostate Cancer Cells Stimulated by BMP-2.

Authors:  Lifeng Lao; Jia Shen; Haijun Tian; Qingqiang Yao; Yawei Li; Lie Qian; Samuel S Murray; Jeffrey C Wang
Journal:  Anticancer Res       Date:  2016-11       Impact factor: 2.480

5.  Inhibition of Cell Growth of the Prostate Cancer Cell Model LNCaP by Cold Atmospheric Plasma.

Authors:  Martin Weiss; Denis Gümbel; Nadine Gelbrich; Lars-Ove Brandenburg; Robert Mandelkow; Uwe Zimmermann; Patrick Ziegler; Martin Burchardt; Matthias B Stope
Journal:  In Vivo       Date:  2015 Sep-Oct       Impact factor: 2.155

6.  Dose-escalation of whole-brain radiotherapy for brain metastasis in patients with a favorable survival prognosis.

Authors:  Dirk Rades; Annika Panzner; Liesa Dziggel; Tiina Haatanen; Radka Lohynska; Steven E Schild
Journal:  Cancer       Date:  2011-12-13       Impact factor: 6.860

7.  In Vitro Cultivation of Primary Prostate Cancer Cells Alters the Molecular Biomarker Pattern.

Authors:  Anne Caspar; Jörg Mostertz; Merle Leymann; Patrick Ziegler; Katja Evert; Matthias Evert; Uwe Zimmermann; Lars-Ove Brandenburg; Martin Burchardt; Matthias B Stope
Journal:  In Vivo       Date:  2016 09-10       Impact factor: 2.155

8.  Reduction of overall treatment time in patients irradiated for more than three brain metastases.

Authors:  Dirk Rades; Susanne Kieckebusch; Radka Lohynska; Theo Veninga; Lukas J A Stalpers; Juergen Dunst; Steven E Schild
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-08-06       Impact factor: 7.038

Review 9.  Whole-brain radiotherapy in the management of brain metastasis.

Authors:  Deepak Khuntia; Paul Brown; Jing Li; Minesh P Mehta
Journal:  J Clin Oncol       Date:  2006-03-10       Impact factor: 44.544

10.  Validation of a survival score for patients treated with whole-brain radiotherapy for brain metastases.

Authors:  L Dziggel; B Segedin; N H Podvrsnik; I Oblak; S E Schild; D Rades
Journal:  Strahlenther Onkol       Date:  2013-03-23       Impact factor: 3.621

View more
  2 in total

1.  Cranial Radiotherapy for Prostate Cancer Patients With Brain Metastases Inaccessible to Stereotactic Radiotherapy.

Authors:  Christina Schröder; Paul Windisch; Jamie Lütscher; Daniel R Zwahlen; Robert Förster
Journal:  In Vivo       Date:  2022 Jul-Aug       Impact factor: 2.406

2.  Validation of a Survival Score for Patients Receiving Radiosurgery or Fractionated Stereotactic Radiotherapy for 1 to 3 Brain Metastases.

Authors:  Dirk Rades; Oliver Blanck; Mai Trong Khoa; Pham VAN Thai; Nguyen Quang Hung; Liesa Dziggel; Steven E Schild
Journal:  In Vivo       Date:  2018 Mar-Apr       Impact factor: 2.155

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.